Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Impact of the COVID-19 pandemic on treat-to-target strategies and physical consultations in >7000 patients with inflammatory arthritis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Glintborg, Bente ; Jensen, Dorte Vendelbo ; Terslev, Lene ; Jensen, Mogens Pfeiffer ; Hendricks, Oliver ; Østergaard, Mikkel ; Engel, Sara ; Rasmussen, Simon Horskjær ; Adelsten, Thomas ; Colic, Ada ; Danebod, Kamilla ; Kildemand, Malene ; Loft, Anne Gitte ; Munk, Heidi Lausten ; Pedersen, Jens Kristian ; Østgård, René Drage ; Møller Sørensen, Christian ; Krogh, Niels Steen ; Nørgaard Agerbo, Jette ; Ziegler, Connie ; Hetland, Merete Lund. / Impact of the COVID-19 pandemic on treat-to-target strategies and physical consultations in >7000 patients with inflammatory arthritis. I: Rheumatology (Oxford, England). 2021 ; Bind 60, Nr. SI. s. SI3-SI12.

Bibtex

@article{857d7717369549ad82b99fb9c74077e7,
title = "Impact of the COVID-19 pandemic on treat-to-target strategies and physical consultations in >7000 patients with inflammatory arthritis",
abstract = "OBJECTIVES: To explore the impact of the COVID-19 pandemic on treat-to-target strategies (disease activity, remission rates) and access to physical consultations in patients with inflammatory rheumatic disease, as well as to explore characteristics of patients with/without physical consultations in the clinic and the impact of early vs established disease.METHODS: Patients with RA, PsA or axial SpA (axSpA) prospectively followed in the nationwide DANBIO registry answered online questionnaires and reported patient-reported outcomes (PROs) in June and November 2020. Patient characteristics, disease activity and physical consultations in the clinic before and during the pandemic were identified in DANBIO [all patients and subgroups with early disease (disease duration ≤2 years)]. In individual patients, changes in PROs before and during the pandemic were calculated. Characteristics of patients with/without physical consultations were described (age, gender, education level, comorbidities, disease duration, treatment).RESULTS: We included 7836 patients (22% of eligible patients), 12% of which had early disease. PROs were stable before and during the pandemic, with median changes approximating zero, as well as in patients with early disease. Remission rates were stable. The relative decrease in the number of patients with physical consultations was 21-72%, which was highest in axSpA. Characteristics of patients with/without physical consultations were similar. Self-reported satisfaction with treatment options and access was >70%; the preferred contact form was physical consultation (66%).CONCLUSION: In this nationwide study performed during the first 8 months of the pandemic, patient satisfaction was high and the PROs and remission rates remained stable despite the remarkable reduction in physical consultations, as well as in patients with early disease. Characteristics of patients with/without physical consultations appeared similar.",
keywords = "Adult, Aged, Arthritis, Psoriatic/therapy, Arthritis, Rheumatoid/therapy, COVID-19, Denmark, Female, Health Services Accessibility/statistics & numerical data, Humans, Male, Middle Aged, Patient Acceptance of Health Care/statistics & numerical data, Patient Reported Outcome Measures, Prospective Studies, Referral and Consultation/statistics & numerical data, Registries, Remission Induction, SARS-CoV-2, Severity of Illness Index, Spondylarthritis/therapy, Treatment Outcome",
author = "Bente Glintborg and Jensen, {Dorte Vendelbo} and Lene Terslev and Jensen, {Mogens Pfeiffer} and Oliver Hendricks and Mikkel {\O}stergaard and Sara Engel and Rasmussen, {Simon Horskj{\ae}r} and Thomas Adelsten and Ada Colic and Kamilla Danebod and Malene Kildemand and Loft, {Anne Gitte} and Munk, {Heidi Lausten} and Pedersen, {Jens Kristian} and {\O}stg{\aa}rd, {Ren{\'e} Drage} and {M{\o}ller S{\o}rensen}, Christian and Krogh, {Niels Steen} and {N{\o}rgaard Agerbo}, Jette and Connie Ziegler and Hetland, {Merete Lund}",
note = "{\textcopyright} The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com. COPECARE",
year = "2021",
month = oct,
day = "9",
doi = "10.1093/rheumatology/keab500",
language = "English",
volume = "60",
pages = "SI3--SI12",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "SI",

}

RIS

TY - JOUR

T1 - Impact of the COVID-19 pandemic on treat-to-target strategies and physical consultations in >7000 patients with inflammatory arthritis

AU - Glintborg, Bente

AU - Jensen, Dorte Vendelbo

AU - Terslev, Lene

AU - Jensen, Mogens Pfeiffer

AU - Hendricks, Oliver

AU - Østergaard, Mikkel

AU - Engel, Sara

AU - Rasmussen, Simon Horskjær

AU - Adelsten, Thomas

AU - Colic, Ada

AU - Danebod, Kamilla

AU - Kildemand, Malene

AU - Loft, Anne Gitte

AU - Munk, Heidi Lausten

AU - Pedersen, Jens Kristian

AU - Østgård, René Drage

AU - Møller Sørensen, Christian

AU - Krogh, Niels Steen

AU - Nørgaard Agerbo, Jette

AU - Ziegler, Connie

AU - Hetland, Merete Lund

N1 - © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com. COPECARE

PY - 2021/10/9

Y1 - 2021/10/9

N2 - OBJECTIVES: To explore the impact of the COVID-19 pandemic on treat-to-target strategies (disease activity, remission rates) and access to physical consultations in patients with inflammatory rheumatic disease, as well as to explore characteristics of patients with/without physical consultations in the clinic and the impact of early vs established disease.METHODS: Patients with RA, PsA or axial SpA (axSpA) prospectively followed in the nationwide DANBIO registry answered online questionnaires and reported patient-reported outcomes (PROs) in June and November 2020. Patient characteristics, disease activity and physical consultations in the clinic before and during the pandemic were identified in DANBIO [all patients and subgroups with early disease (disease duration ≤2 years)]. In individual patients, changes in PROs before and during the pandemic were calculated. Characteristics of patients with/without physical consultations were described (age, gender, education level, comorbidities, disease duration, treatment).RESULTS: We included 7836 patients (22% of eligible patients), 12% of which had early disease. PROs were stable before and during the pandemic, with median changes approximating zero, as well as in patients with early disease. Remission rates were stable. The relative decrease in the number of patients with physical consultations was 21-72%, which was highest in axSpA. Characteristics of patients with/without physical consultations were similar. Self-reported satisfaction with treatment options and access was >70%; the preferred contact form was physical consultation (66%).CONCLUSION: In this nationwide study performed during the first 8 months of the pandemic, patient satisfaction was high and the PROs and remission rates remained stable despite the remarkable reduction in physical consultations, as well as in patients with early disease. Characteristics of patients with/without physical consultations appeared similar.

AB - OBJECTIVES: To explore the impact of the COVID-19 pandemic on treat-to-target strategies (disease activity, remission rates) and access to physical consultations in patients with inflammatory rheumatic disease, as well as to explore characteristics of patients with/without physical consultations in the clinic and the impact of early vs established disease.METHODS: Patients with RA, PsA or axial SpA (axSpA) prospectively followed in the nationwide DANBIO registry answered online questionnaires and reported patient-reported outcomes (PROs) in June and November 2020. Patient characteristics, disease activity and physical consultations in the clinic before and during the pandemic were identified in DANBIO [all patients and subgroups with early disease (disease duration ≤2 years)]. In individual patients, changes in PROs before and during the pandemic were calculated. Characteristics of patients with/without physical consultations were described (age, gender, education level, comorbidities, disease duration, treatment).RESULTS: We included 7836 patients (22% of eligible patients), 12% of which had early disease. PROs were stable before and during the pandemic, with median changes approximating zero, as well as in patients with early disease. Remission rates were stable. The relative decrease in the number of patients with physical consultations was 21-72%, which was highest in axSpA. Characteristics of patients with/without physical consultations were similar. Self-reported satisfaction with treatment options and access was >70%; the preferred contact form was physical consultation (66%).CONCLUSION: In this nationwide study performed during the first 8 months of the pandemic, patient satisfaction was high and the PROs and remission rates remained stable despite the remarkable reduction in physical consultations, as well as in patients with early disease. Characteristics of patients with/without physical consultations appeared similar.

KW - Adult

KW - Aged

KW - Arthritis, Psoriatic/therapy

KW - Arthritis, Rheumatoid/therapy

KW - COVID-19

KW - Denmark

KW - Female

KW - Health Services Accessibility/statistics & numerical data

KW - Humans

KW - Male

KW - Middle Aged

KW - Patient Acceptance of Health Care/statistics & numerical data

KW - Patient Reported Outcome Measures

KW - Prospective Studies

KW - Referral and Consultation/statistics & numerical data

KW - Registries

KW - Remission Induction

KW - SARS-CoV-2

KW - Severity of Illness Index

KW - Spondylarthritis/therapy

KW - Treatment Outcome

UR - http://www.scopus.com/inward/record.url?scp=85118285880&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/keab500

DO - 10.1093/rheumatology/keab500

M3 - Journal article

C2 - 34146099

VL - 60

SP - SI3-SI12

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - SI

ER -

ID: 70406608